After PSM, the MAFLD group still had a higher HbA1c level; higher BMI; larger waist circumference; higher BFP; higher basal metabolic rate; higher total cholesterol, LDL-C, remnant cholesterol, CRP, ALT, AST, ALP, and GGT levels; higher FIB-4 score and NFS; lower HDL-C level; and higher prevalence rates of CKD, DM, prediabetes, overweight/obesity, albuminuria, hyperuricemia, and hypertriglyceridemia than the non-MAFLD group. The gene discussed is GPT; the disease is Obesity.